These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16960151)

  • 21. The results of imatinib therapy for patients with primary eosinophilic disorders.
    Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
    Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
    [No Abstract]   [Full Text] [Related]  

  • 22. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
    Stentoft J; Pallisgaard N; Kjeldsen E; Holm MS; Nielsen JL; Hokland P
    Eur J Haematol; 2001; 67(5-6):302-8. PubMed ID: 11872078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate in the treatment of hematologic malignancies.
    Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
    Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.
    Grand FH; Burgstaller S; Kühr T; Baxter EJ; Webersinke G; Thaler J; Chase AJ; Cross NC
    Cancer Res; 2004 Oct; 64(20):7216-9. PubMed ID: 15492236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.
    Baxter EJ; Kulkarni S; Vizmanos JL; Jaju R; Martinelli G; Testoni N; Hughes G; Salamanchuk Z; Calasanz MJ; Lahortiga I; Pocock CF; Dang R; Fidler C; Wainscoat JS; Boultwood J; Cross NC
    Br J Haematol; 2003 Jan; 120(2):251-6. PubMed ID: 12542482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
    Gallagher G; Horsman DE; Tsang P; Forrest DL
    Cancer Genet Cytogenet; 2008 Feb; 181(1):46-51. PubMed ID: 18262053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
    Martinelli G; Iacobucci I; Rosti G; Pane F; Amabile M; Castagnetti F; Cilloni D; Soverini S; Testoni N; Specchia G; Merante S; Zaccaria A; Frassoni F; Saglio G; Baccarani M
    Ann Oncol; 2006 Mar; 17(3):495-502. PubMed ID: 16403813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.
    Xu X; Lu Q; Wang Z; Cai P; Zeng Z; Zhang L; Wang M; Ma L; Ruan C; Chen S
    Cancer Res Treat; 2021 Jul; 53(3):889-892. PubMed ID: 33421986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.
    Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB
    Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854
    [No Abstract]   [Full Text] [Related]  

  • 32. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib.
    Yao S; Na L; Liangding H
    Ann Hematol; 2024 Aug; 103(8):3247-3250. PubMed ID: 38888615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
    Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
    Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.
    Naumann N; Schwaab J; Metzgeroth G; Jawhar M; Haferlach C; Göhring G; Schlegelberger B; Dietz CT; Schnittger S; Lotfi S; Gärtner M; Dang TA; Hofmann WK; Cross NC; Reiter A; Fabarius A
    Genes Chromosomes Cancer; 2015 Dec; 54(12):762-70. PubMed ID: 26355392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of chronic myeloproliferative disease-unclassifiable (CMPD-U) with no chromosomal abnormalities by imatinib mesylate.
    Iyama S; Matsunaga T; Sato T; Murase K; Araki N; Takimoto R; Kobune M; Sagawa T; Takayama T; Niitsu Y
    Intern Med; 2008; 47(8):791-4. PubMed ID: 18421200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).
    Kulkarni S; Heath C; Parker S; Chase A; Iqbal S; Pocock CF; Kaeda J; Cwynarski K; Goldman JM; Cross NC
    Cancer Res; 2000 Jul; 60(13):3592-8. PubMed ID: 10910073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.
    Sakamoto Y; Mariya Y; Oshikiri T; Sasaki S; Segawa M; Teshiromori R; Ogura K; Akagi T; Kaimori M; Kubo K
    Acta Med Okayama; 2011 Oct; 65(5):335-42. PubMed ID: 22037271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib.
    Wilkinson K; Velloso ER; Lopes LF; Lee C; Aster JC; Shipp MA; Aguiar RC
    Blood; 2003 Dec; 102(12):4187-90. PubMed ID: 12907457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.